Surf Wiki
Save to docs
general/experimental-cancer-drugs

From Surf Wiki (app.surf) — the open knowledge base

Laniquidar

Chemical compound

Chemical compound

| elimination_half-life =

Laniquidar (INN) is a third generation P-glycoprotein inhibitor that underwent clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It has been discontinued because of its low bioavailability and a high variability with how the patients responded to the drug.

Clinical Trials

Laniquidar has been tested for its efficacy for treating refractory breast cancer together with docetaxel and paclitaxel. Phase 2 clinical trials began in September 2001 by the European Organization for Research and Treatment of Cancer (EORTC) which included 35 participants. These patients have not responded to prior chemotherapy treatments. The study ended in June 2002 but the results have not been reported.

Chemistry

Laniquidar is a benzazepine. The chemical name for Laniquidar is methyl 11-(1-(4-quinolin-2-ylmethoxy)phenethyl)piperidin-4ylidene)-6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepine-3-carboxylate and its free base form has a chemical formula of C37H36N4O3 with a molecular weight of 584.720 g/mol.

Mechanism of Action

Laniquidar is a highly selective P-Glycoprotein (P-gp) inhibitor that also has a high lipophilicity. P-gp is a mulit-drug resistant protein that causes the efflux of substrates such as chemotherapeutic drugs out of the cell. Laniquidar works to inhibit the efflux by causing a conformational change of P-gp. This hinders ATP hydrolysis and the substrate can not be positioned to leave the cell since the permeability of the cell membrane decreases.

References

References

  1. (December 2004). "Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome". Best Practice & Research. Clinical Haematology.
  2. Reina., Sosnik, Alejandro. Bendayan. (2020). "Drug efflux pumps in cancer resistance pathways : from molecular recognition and characterization to possible inhibition strategies in chemotherapy". Academic Press.
  3. (17 July 2012). "R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy - Tabular View - ClinicalTrials.gov".
  4. PubChem. "Laniquidar".
  5. (April 2003). "Seminars in radiation oncology". Nuclear Medicine and Biology.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

experimental-cancer-drugs quinolines phenol-ethers piperidines nitrogen-heterocycles heterocyclic-compounds-with-3-rings
Want to explore this topic further?

Ask Mako anything about Laniquidar — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report